The ADC payload landscape has seen momentum shift in recent years. Driven by clinical success of the DXd platform, the ADC community have now locked on to topoisomerase I inhibitors as the go-to payload. However, there is also a growing movement to explore the next series of payload innovation from PROTACs to novel MoA cytotoxic payloads.
As part of the World ADC Series, the inaugural ADC Payload Summit will deep dive into how to build upon the success of topoisomerase I inhibitors through chemical optimization and showcase novel approaches in payload selection and development. This will enable you to expand your toolbox of ADC payloads to improve efficacy, diversify mode of action and overcome resistance challenges.
As the first and only conference exclusively focusing on ADC Payloads, you can expect to learn about fine-tuning payload structure to improve catalytic mechanisms of topoisomerase I inhibitors, showcase non-camptothecin topoisomerase I payloads as an improved ADC payload, validate N-Myristoyltransferase, RNA Polymerase II inhibitors and KIF20A Kinesin as ADC payloads, whilst also exploring the how degraders can offer improved safety and efficacy of existing payload options.
The agenda has been designed for chemists and medicinal chemists from within the ADC sphere who are looking at understanding how they can make structural chemical alterations to optimize well-explored payloads, and also to assess the potential future application of novel payload that provide alternative mode of actions and are less susceptible to resistance mechanisms that currently plague ADC payloads.
With confirmed experts including Merck KGaA, Orum Therapeutics, Tubulis, Takeda, and many more; this is your chance to stay abreast of trends in payload development and stay ahead of innovation so that you are maximizing and widening the applicability of your ADC pipeline through a variety of MoAs and indications.
